Rationale: Oxidative stress in rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons for the maintenance of neurogenic vasomotor tone are located, contributes to neural mechanisms of hypertension. Emerging evidence suggests that brain-derived neurotrophic factor (BDNF) manifests "nontrophic" actions.
O xidative stress resulting from an imbalance of production over degradation of the reactive oxygen species (ROS), particularly superoxide anion (O 2 . ), is associated with hypertension. 1, 2 In the rostral ventrolateral medulla (RVLM), where sympathetic premotor neurons for the maintenance of vasomotor tone are located, 3 overproduction of O 2 . plays a pivotal role in neural mechanism of hypertension by increasing sympathetic outflow to the peripheral blood vessels. 1,2,4 -6 Thus, NADPH oxidase-derived O 2 . in RVLM mediates chronic pressor response induced by angiotensin II (Ang II). 7 A decrease in molecular synthesis and enzyme activity of superoxide dismutase (SOD) isoforms contributes to hyper-tensive phenotype in the spontaneously hypertensive rats (SHRs). 6 On the other hand, transcriptional upregulation of mitochondrial uncoupling protein (UCP)2 abrogates Ang II-induced oxidative stress and alleviates oxidative stressassociated neurogenic hypertension via a negative-feedback mechanism. 8 One of the well-recognized protective mechanisms against stressful insults in brain is expression of neurotrophic factors, in particular brain-derived neurotrophic factor (BDNF). 9 Superimposed on its "classic" trophic functions in proliferation, differentiation, and survival of neurons in the peripheral and central nervous system during development, 10 or in synaptic activity and plasticity of mature neurons, 11 attention has begun to shift to the "nontrophic" neuroprotective actions of BDNF, 12 which defend neurons against injury and disease. 13 However, whether BDNF induces neuroprotection via amelioration of tissue oxidative stress is elusive. BDNF protects striatal neurons from cell death as an antioxidant. 14 On the other hand, BDNF causes oxidative stress in cortical cells via activation of NADPH oxidase and overproduction of ROS. 15 Likewise, the effect of oxidative stress on BDNF expression or function is controversial. ROS at a moderate level stimulates BDNF expression in the spinal cord through redox-sensitive transcription. 16 Paradoxically, oxidative stress elicited by high levels of O 2 . inhibits secretion of BDNF from cerebral endothelial cells. 17 BDNF and the tropomyosin receptor kinase (Trk)B are distributed in brainstem nuclei that subserve neural regulation of arterial pressure, 18, 19 although there is currently no evidence indicating the engagement of redox-sensitive BDNF signaling in this regulatory process. The present study tested the hypothesis that BDNF may play an active role in oxidative stress-associated neurogenic hypertension by participating in the maintenance of ROS, particularly O 2 . homeostasis in RVLM.
Methods
All experimental procedures were carried out in compliance with the guidelines of our institutional animal care committee. Adult (12- week-old) male normotensive Wistar-Kyoto (WKY) rats or SHRs purchased from the Experimental Animal Center of the National Applied Research Laboratories, Taiwan, were used. Animals received intracisternal infusion or microinjection bilaterally into RVLM of Ang II, alone or with additional treatment with BDNF; a SOD mimetic, tempol; an inhibitor of NADPH oxidase assembly, apocynin; an angiotensin subtype 1 receptor (AT 1 R) antagonist, losartan; an antisense oligonucleotide (ASON) against p47 phox sub-unit of NADPH oxidase, cAMP response element binding protein (CREB) or BDNF; or recombinant human TrkB-Fc chimera, which sequesters endogenously released TrkB ligands (BDNF and neurotrophin-4) and blocks the TrkB receptors, 20 or TrkA-Fc chimera. The dose of molecular reagents used in this study was modified from previous studies that validated the selectivity/effectiveness of the chemicals. 5,20 -23 The key experimental procedures included measurement of mean arterial pressure (MAP) and heart rate by radiotelemetry under conscious conditions or in animals maintained under propofol anesthesia [5] [6] [7] [8] ; determination of mRNA by reverse-transcription real-time PCR or protein expression by Western blot 8 ; determination of BDNF tissue level by a fluorometric 2-site enzyme immunoassay (ELISA); measurement of enzyme activity of nicotinamide-adenine dinucleotide cytochrome c reductase (NCCR) (marker for electron coupling capacity between complexes I and III), succinate cytochrome c reductase (SCCR) (marker for electron coupling capacity between complexes II and III), 24 or mitochondrial or cytosolic SOD 6, 24 ; quantification of tissue level of O 2 . by lucigenin-enhanced chemiluminescence assay [5] [6] [7] [8] and immunofluorescence staining coupled with laser scanning confocal microscopy for location of BDNF in RVLM neurons. 25 Data are expressed as meansϮSEM. The statistical software SigmaStat (SPSS, Chicago, Ill) was used for data analysis. One-way or 2-way ANOVA with repeated measures was used, as appropriate, to assess group means, followed by the Scheffé multiple-range test for post hoc assessment of individual means. Probability values of Ͻ0.05 were considered statistically significant.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results

Ang II-Induced Increases in Protein Expression and Tissue Level of BDNF in RVLM Are Dependent on NADPH Oxidase-Derived Superoxide Anion
Our laboratory reported previously 5 that Ang II induces oxidative stress by increasing O 2 . production in RVLM via activation of NADPH oxidase. We took advantage of this cellular event in our first series of experiments to investigate whether acute site-specific induction of oxidative stress by Ang II in RVLM affects BDNF expression in WKY rats. Microinjection bilaterally into RVLM of Ang II (100 pmol) induced a progressive increase in BDNF mRNA ( Figure 1A ) or protein ( Figure 1B ) expression that became significant 4 hours after application of the octapeptide, reaching a maximum at 8 hours, and endured at least 24 hours. The maximal Ang II-induced upregulation of BDNF protein expression was significantly blunted on coadministration of an inhibitor of NADPH oxidase assembly, apocynin (2 nmol), or by gene knockdown with ASON against p47 phox subunit of NADPH oxidase (200 pmol) (data not shown). The Ang II-induced BDNF upregulation was also inhibited by coadministration of an AT 1 R antagonist, losartan (2 nmol). Ang II, on the other hand, exerted no effect on baseline BDNF expression in RVLM of WKY rats (Online Figure I , A).
To further investigate the effect of chronic oxidative stress on BDNF expression in RVLM, Ang II was microinfused into the cisterna magna via an osmotic minipump for 7 days. Intracisternal infusion of Ang II (100 ng⅐L Ϫ1 ⅐h Ϫ1 ) increased BDNF protein expression ( Figure 1C ) and tissue level ( Figure  1D ) of BDNF detected at 12, 24, 48, or 72 hours or days 5 and 7 (data not shown) after infusion. This induced increase, detected on 48 or 72 hours after infusion, was attenuated by Figure 1E ). In a separate series of experiments, we found no significant increase in BDNF protein expression in RVLM of SHRs, where oxidative stress has been demonstrated previously. 6, 26, 27 ROS inhibition also did not affect its expression (Online Figure I, B ).
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Superoxide-Dependent Phosphorylation of CREB Mediates BDNF Upregulation by Ang II
Phosphorylation of CREB, a transcription factor for the induction of bdnf mRNA in brain, 28 is redox-sensitive. 29 Our second series of experiments therefore examined the involvement of CREB in Ang II-induced BDNF upregulation in RVLM of WKY rats. Microinjection bilaterally into RVLM of Ang II (100 pmol) induced phosphorylation of CREB at Ser133, detected 30, 60, or 120 minutes after injection ( Figure 2A ). The Ang II-induced CREB phosphorylation, when determined 60 minutes after infection, was significantly blunted by coadministration of a SOD mimetic, tempol (100 pmol), or apocynin (2 nmol). Gene knockdown of CREB expression by microinjection bilaterally into RVLM of CREB ASON (100 or 200 pmol), 24 hours before octapeptide administration, effectively suppressed CREB mRNA expression (Online Figure II , A) and significantly reduced the BDNF mRNA upregulation in RVLM detected 8 hours after Ang II administration ( Figure 2B ). Control microin- 
BDNF Is Involved in Regulation of Chronic O 2 .
Production in RVLM After Intracisternal Infusion of Ang II
We next delineated whether BDNF plays a role in ROS homeostasis at RVLM of WKY rats based on gene knockdown of BDNF or blockade of TrkB. Microinjection bilaterally into RVLM of a BDNF ASON (100 or 200 pmol) that effectively reduced BDNF mRNA and protein expression (Online Figure II , B) or recombinant human TrkB-Fc (1 or 5 nmol), but not TrkA-Fc (5 nmol), fusion protein that sequesters endogenously released TrkB ligands and blocks TrkB, 20 24 hours or 1 hour, respectively, before O 2 . measurement, significantly potentiated the increase in O 2 . production in RVLM measured 24 hours after intracisternal infusion of the octapeptide (100 ng⅐L Ϫ1 ⅐h Ϫ1 ) ( Figure 3A ). Similar to our previous observations, 5 
BDNF Attenuates Ang II-Induced Phosphorylation of p47 phox Subunit of NADPH Oxidase in RVLM
We reported previously 5 that phosphorylation of serine residue of p47 phox subunit of NADPH oxidase is an important step for the AT 1 R-dependent O 2 . production induced by Ang II in RVLM. Our fifth series of experiments determined whether BDNF exerts protection against the Ang II-evoked oxidative stress in RVLM of WKY rats by targeting this cellular event. Microinjection bilaterally into RVLM of BDNF (100 or 250 ng) significantly attenuated the Ang II-induced (100 pmol) serine phosphorylation of p47 phox subunit, detected 30 minutes after infection, with minimal effects on total p47 phox protein expression ( Figure 3B ). On the other hand, gene knockdown (24 hours before Ang II) or receptor blockade (1 hour before Ang II) by microinjection bilaterally into RVLM of BDNF ASON (100 or 200 pmol) or recombinant human TrkB-Fc fusion protein (5 nmol), but not BDNF SON or TrkA-Fc fusion protein, significantly enhanced the Ang II-induced serine phosphorylation of p47 phox subunit. Intriguingly, Ang II-induced p47 phox phosphorylation in RVLM was again inhibited by exogenous BDNF in rats treated with BDNF ASON (Online Figure III) . Of note was that BDNF, its ASON, or TrkB-Fc fusion protein exerted minimal effect on basal protein expression of p40 phox , p67 phox , gp91 phox , or p22 phox subunit of NADPH oxidase in RVLM (Online Figure IV) . Furthermore, phosphorylation of serine residue of p40 phox or p67 phox subunit of NADPH oxidase in RVLM of WKY rats was under detection limit under basal condition or after Ang II (100 pmol) treatment (data not shown).
BDNF Preserves Mitochondrial Electron Coupling Capacity and Upregulates Mitochondrial Uncoupling Protein Expression in RVLM After Intracisternal Infusion of Ang II
We reported recently that NADPH oxidase-derived O 2 . produced by Ang II inhibits the activity of NCCR and SCCR. 24 We further showed that mitochondrial UCP2 acts as an antioxidant under chronic oxidative stress in RVLM via feedback regulation of O 2 . production. 8 It follows that BDNF may chronically regulate the Ang II-evoked O 2 . production in RVLM by preserving mitochondrial electron transport chain functions and/or by upregulating mitochondrial UCP2 expression. Our sixth series of experiments evaluated these 2 possibilities. Intracisternal infusion of Ang II (100 ng⅐L Ϫ1 ⅐h Ϫ1 for 7 days) via osmotic minipump in WKY rats resulted in a significant reduction of NCCR or SCCR activity in RVLM, detected on day 7 after infusion ( Figure 4A ). The Ang II-induced reduction in mitochondrial electron coupling capacities was significantly alleviated in animals that received coinfusion into the cisterna magna of BDNF (0.1 or 0.5 ng⅐L Ϫ1 ⅐h Ϫ1 for 7 days). Coinfusion of BDNF ASON (1 or 5 pmol⅐L Ϫ1 ⅐h Ϫ1 for 7 days), but not the SON, on the other hand, resulted in a dose-related enhancement in Ang IIinduced suppression of NCCR or SCCR activity. In a separate series of experiments, microinjection of Ang II (100 pmol) bilaterally into RVLM upregulated mitochondrial UCP2 protein expression, detected 12 hours after infection ( Figure 4B ). This Ang II-induced upregulation in mitochondrial UCP2 was attenuated by coadministration of BDNF ASON (200 pmol) or recombinant human TrkB-Fc fusion protein (5 nmol). Microinjection bilaterally into RVLM of BDNF (100 or 250 ng), on the other hand, resulted in an increase in mitochondrial UCP2 expression, detected 12 hours after infection. Immunoblot results further demonstrated that both full-length and truncated TrkB receptor proteins were expressed in the mitochondrial fraction of RVLM ( Figure 4C ), although they were minimally affected by BDNF (250 ng) or its ASON (200 pmol).
BDNF Restores the Reduced Mitochondrial Electron Coupling Capacity and Upregulates Mitochondrial UCP2 Expression in RVLM of Spontaneously Hypertensive Rats
We reported previously that mitochondrial dysfunction because of reduced enzyme activities in NCCR and SCCR contributes to chronic oxidative stress in RVLM of SHRs. 24 We reasoned that a role for BDNF-TrkB signaling in the maintenance of O 2 . homeostasis can be further substantiated should BDNF level is reduced in RVLM of SHRs and replacement of BDNF restores mitochondrial function and ameliorates oxidative stress. Compared with normotensive WKY rats, the endogenous level of BDNF was significantly lower ( Figure 5A ) and enzyme activity of NCCR or SCCR significantly reduced ( Figure 5B ) in RVLM of SHRs, accompanied by an elevated tissue level of O 2 . ( Figure 5C ) and an increase in UCP2 protein expression ( Figure 5D ). Infusion of BDNF (0.1 or 0.5 ng⅐L Ϫ1 ⅐h Ϫ1 for 7 days) into the cisterna magna of SHRs resulted in a dose-related increase in BDNF tissue level ( Figure 5A ) that at the higher dose approximated that induced by Ang II (cf, Figure 1D ) and restoration of NCCR or SCCR activity ( Figure 5B ) in RVLM, alongside reduced tissue level of O 2 . ( Figure 5C ) and further increase in UCP2 protein expression ( Figure 5D ). Those effects of BDNF, detected on day 7 after infusion, were significantly blunted by microinjection bilaterally into RVLM of TrkB-Fc (5 nmol) but not TrkA-Fc fusion protein.
BDNF Does Not Affect Protein Expression or Enzyme Activity of SOD Isoforms in RVLM
An increase in antioxidant SOD expression in RVLM has been demonstrated to significantly reduce tissue O 2 . levels. 6, 24 We therefore investigated whether SOD plays a role in the BDNF-promoted protection against Ang II-induced oxidative stress in RVLM. Microinjection bilaterally into RVLM of BDNF (100 or 250 ng) did not alter basal expression of cytosolic SOD1, mitochondrial SOD2 or extracellular SOD3 (Online Figure V , A through C) in WKY rats. BDNF (250 ng) or BDNF ASON (200 pmol) also did not affect the upregulated SOD1 or SOD2 expression detected 2 hours after Ang II (100 pmol) treatment (Online Figure V, A 
BDNF in RVLM Negatively Regulates the Chronic Pressor Response Induced by Intracisternal Infusion of Ang II
Our ninth series of experiments established the functional significance of BDNF at RVLM in cardiovascular phenotype induced by Ang II. Compared with its SON, microinjection bilaterally into RVLM of BDNF ASON (200 pmol) on day 3 after intracisternal infusion of Ang II (100 ng⅐L Ϫ1 ⅐h Ϫ1 for 7 days) significantly potentiated the induced long-term pressor response ( Figure 6A ), measured by radiotelemetry in conscious WKY rats. The Ang II-induced hypertension, detected under anesthetized condition on day 7 after intracisternal infusion, was significantly potentiated in animals that received microinjection bilaterally into RVLM of recombinant human TrkB-Fc, but not TrkA-Fc fusion protein (5 nmol) ( Figure 6B ). Coinfusion of BDNF (0.1, 0.5 or 1 ng⅐L Ϫ1 ⅐h Ϫ1 ) for 7 days into the cisterna magna of WKY rats, on the other hand, attenuated the Ang II-induced long-term pressor response ( Figure 6C ). Intracisternal infusion of BDNF alone promoted no significant change in basal MAP.
BDNF in RVLM Promotes Antihypertension in SHRs
Sustained oxidative stress in RVLM contributes to neurogenic hypertension in SHRs. 2, 8, 24 To establish that depression of BDNF/TrkB signaling in the RVLM is involved in manifestation of neurogenic hypertension, we determined the cardiovascular responses to intracisternal infusion of BDNF (0.1 or 0.5 ng⅐L Ϫ1 ⅐h Ϫ1 for 7 days). Compared with vehicle control, BDNF infusion resulted in a gradual decrease in MAP, monitored by radiotelemetry in conscious SHRs (Figure 7A) . This antihypertensive effect of BDNF was accompanied by a slight decrease in heart rate (data not shown). The BDNF-induced (0.5 ng⅐L Ϫ1 ⅐h Ϫ1 ) hypotension, measured on day 7 in the anesthetized SHRs following intracisternal infusion of the trophic factor, was antagonized by microinjection bilaterally into RVLM of recombinant human TrkB-Fc (1 or 5 nmol) fusion protein ( Figure 7B ). Figure VI) . The same treatments also did not significantly affect basal MAP (Online Figure VII) or heart rate (data not shown) over 24 hours.
Endogenous BDNF Is Not Involved in Tonic
Discussion
A dysregulation of ROS production and/or elimination in brain plays a pivotal role in the pathophysiology of a number of cardiovascular diseases, including stroke, 30 heart failure, 31 and hypertension. [1] [2] [3] [5] [6] [7] [8] 24 Given its significance in the regulation of cardiovascular hemodynamics, there is a clear need to gain better insights into mechanisms for the maintenance of ROS homeostasis. Toward this end, the present study unveils a novel role for BDNF/TrkB signaling in O 2 . homeostasis in RVLM and the associated cardiovascular phenotype. To our knowledge, ours is the first report on active engagement of BDNF in oxidative stress-associated neurogenic hypertension via negative-feedback regulation of tissue O 2 . levels in RVLM (Figure 8 ). Our results also indicated that disruption of BDNF/TrkB signaling is involved in the manifestation of oxidative stress-associated neurogenic hypertension in SHRs. Apart from its well-characterized actions as a trophic factor, accumulating evidence suggests that BDNF exhibits "nontrophic" neuroprotective actions. Whether BDNF protects the brain against oxidative stress, however, is controversial. The present study provided in vivo data to support an production in RVLM. Confocal microscopic images further indicate that the NADPH oxidase-sensitive increases in BDNF protein expression are distributed in RVLM neurons. We confirmed that the green fluorescence signals that were not colocalized with the neuronal marker NeuN (neuronspecific nuclear protein) were genuine BDNF immunoreactivity in RVLM because the signal was absent in control brainstem sections in which anti-BDNF antiserum was omitted from the incubation medium. Because a recent study 32 reported the expression of BDNF in primary rat astrocytes, the implicated presence of BDNF in glial cells in RVLM cannot be excluded. Our differential results from treatments with TrkB-Fc and TrkA-Fc further suggest that the antioxidant effect of BDNF against Ang II-induced oxidative stress in RVLM is mediated via TrkB. Activation of TrkB has been demonstrated to be engaged in neuroprotection against cerebrovascular disease by BDNF. 33, 34 The negligible effect of ROS inhibition on basal BDNF expression in RVLM argues for activation of the BDNF/TrkB signaling when tissues are exposed to oxidative insults. However, the design of the present study does not allow us to preclude the possibility that the Ang II-induced BDNF upregulation might take place in other brain sites. A recent study 35 based on microarray analysis of human adrenocortical cells showed that bdnf gene is one of the most upregulated by Ang II. The precise mechanisms that underlie the redox-sensitive transcriptional regulation of BDNF in brain are not fully elucidated. We identified in the present study that one signaling molecule that interposes between Ang II-induced oxidative stress and transcriptional activation of BDNF in RVLM is CREB. We reported previously that the Ang II-induced increase in O 2 . production in RVLM occurs within 10 minutes after infection. 5 The temporal profiles demonstrated in the present study revealed that phosphorylation of CREB at Ser133 in RVLM took place 30 minutes after application of Ang II, followed by upregulation of BDNF mRNA transcription 4 hours later. A permissive role for CREB phosphorylation in mediating the redox-sensitive upregulation of BDNF by Ang II was further ascertained by observations that treatment with NADPH oxidase inhibitor, p47 phox ASON or SOD mimetic attenuated the Ang IIinduced phosphorylation of CREB. Moreover, gene knockdown of CREB expression significantly blunted the Ang II-promoted upregulation of BDNF mRNA. CREB is a key transcription factor for BDNF induction, 28 and phosphorylation of Ser133 is a central event in the activation of CREB and CRE-dependent BDNF gene transcription. 36 In transgenic mice in which CREB-mediated transcription is repressed, the neuroprotective effect of BDNF against ROSmediated cytotoxicity is abrogated. 14 Our findings of a minimal effect by CREB ASON treatment on basal BDNF expression again argues for a redox-sensitive activation of this transcription factor. In this regard, oxidants such as hydrogen peroxide initiates an influx of extracellular calcium that leads to CREB phosphorylation in lung epithelial cells. 29 Inhibition of enzymatic production of O 2 . and/or potentiation of cellular antioxidant defense mechanisms lessens tissue oxidative stress. We demonstrated in the present study that BDNF may alleviate Ang II-induced elevation in O 2 . levels in RVLM by at least 3 mechanisms. First, BDNF suppresses Ang II-induced phosphorylation of p47 phox subunit of NADPH oxidase, with minimal effect on phosphorylation of p40 phox or p67 phox subunit or protein expression of membrane (gp91 phox or p22 phox ) or cytosolic (p40 phox , p47 phox or p67 phox ) subunits. NADPH oxidase is a major enzyme for Ang II-elicited O 2 . production in RVLM, 1, 8 and its activation is a multistep process that is initiated by serine phosphorylation of the cytosolic regulatory p47 phox subunit. 8, 37 We noted, however, that those in vivo observations contradict earlier in vitro studies 15, 38 in which BDNF reportedly activates NADPH oxidase. Differences in experimental design (in vivo against in vitro studies) and dose or duration of BDNF treatment may account for these discrepancies. Second, BDNF preserves the mitochondrial electron coupling capacity in RVLM. During normal cellular respiration, O 2 . is produced by a reaction between O 2 and electrons leaked from the mitochondrial electron transport chain. A reduction in the electron coupling capacity between complexes I and III or complexes II and III thus results in ROS generation, 39 and contributes to chronic oxidative stress in RVLM that is associated with neurogenic hypertension. 24 By preserving NCCR and SCCR activities in RVLM, the upregulated BDNF may thus exert a feedback regulation on cellular ROS level by decreasing mitochondrial O 2 . production. This notion is further supported by observations that there was a reduction in BDNF expression and NCCR and SCCR activity, alongside an augmented tissue level of O 2 . in RLVM of SHRs. Importantly, replacement of BDNF restored the reduced mitochondrial electron coupling capacity, resulting in amelioration of oxidative stress in RVLM of SHRs. BDNF has been demonstrated to increase respiratory coupling at complex I in pure rat brain mitochondrial preparations. 40 Third, BDNF upregulates the expression of mitochondrial antioxidant UCP2. UCP2 is a homolog of UCP protein family of mitochondrial anion transporters that uncouple ATP synthesis from oxidative phosphorylation by causing proton leakage across the mitochondrial inner membrane, leading to a decrease in proton electrochemical gradient across the inner mitochondrial membrane and the resultant mitigation in the production of mitochondria-derived ROS, in particular O 2 . .
We reported recently 8 that transcriptional upregulation of mitochondrial UCP2 in response to oxidative stress plays an active role in feedback regulation of ROS production in RVLM. By potentiating the Ang II-induced upregulation of UCP2 expression, it is conceivable that BDNF may regulate ROS homeostasis by potentiating this antioxidant mechanism in RVLM. This notion is further supported by observations that an increase of BDNF upregulated UCP2 expression and ameliorated the augmented tissue level of O 2 . in RVLM of SHRs. The cellular mechanisms underlying BDNF-induced UCP2 upregulation await further elucidation. Our finding that both full-length and truncated TrkB receptor proteins are expressed in the mitochondrial fraction of tissue samples from RVLM suggests that BDNF may regulate UCP2 expression as a signaling molecule that targets the mitochondria. Our data, on the other hand, indicate that SODs may not be the targets of BDNF in the maintenance of ROS homeostasis because basal and Ang II-induced increases in protein ex-pression and enzyme activity of SOD isoforms were not affected by the neurotrophin. Accumulating evidence [5] [6] [7] [8] 24 indicates that Ang II-induced oxidative stress in RVLM plays a pivotal role in neural mechanism of hypertension. We demonstrated in the present study that feedback regulation of ROS by the Ang II-induced upregulation of BDNF is functionally significant in central regulation of arterial pressure. Coinfusion of BDNF attenuated the long-term pressor response evoked by intracisternal infusion of Ang II. Gene knockdown of BDNF or blockade of TrkB, on the other hand, augmented the Ang II-induced hypertension. In RVLM of SHRs, which exhibits heightened tissue level of O 2 . , 6, 24 BDNF that reached a tissue level comparable to that in RVLM of WKY rats on intracisternal infusion ameliorates chronic oxidative stress and promotes TrkB-dependent antihypertension. Our results thus provide novel evidence to support an ameliorative action of BDNF in RVLM on oxidative stress-associated neurogenic hypertension. The negligible effect of endogenous BDNF on basal arterial pressure further ascertains that the BDNF-evoked amelioration of neurogenic hypertension is not secondary to perturbation of basal hemodynamic parameters by the neurotrophin. We noted that whereas exogenous infusion of BDNF reduced the heightened tissue level of O 2 . in RVLM of SHRs to a level comparable to WKY rats, the same treatment promoted only a partial antihypertensive effect. These results are interpreted to suggest that the hypertensive phenotype in SHRs cannot be explained solely by a defect in BDNFregulated ROS homeostasis in RVLM. In addition, whether BDNF participates in central cardiovascular regulation via actions on other brain regions also remains to be investigated. In this regard, BDNF is distributed in the nucleus tractus solitarii and is involved in postdevelopmental modification at first-order synapses in arterial baroreceptor pathways. 41 BDNF also attenuates Ang II-induced and oxidative stressassociated facilitation of calcium channel 42 in this nucleus. 43 We recognize that results obtained from experiments with exogenously administered Ang II are not necessarily applied to the observation in SHRs. In this regard, instead of an anticipated elevation of BDNF level in RVLM of SHRs, which exhibits an increase in tissue level of O 2 . , 6, 26, 27 we found that the protein expression of BDNF was comparable to that in WKY rats and was not affected by ROS inhibition; tissue level of BDNF was significantly less. These results are interpreted to imply a potential defect in oxidative stressassociated transcriptional upregulation of BDNF in RVLM of SHRs. Functional single nucleotide polymorphism of BDNF gene was recently reported to be associated with the development of cardiovascular disease. 44, 45 It is thus tempting to speculate that an inherited variations in BDNF gene in SHRs may render transcriptional regulation of this neurotrophic factor nonresponsive to oxidative stress. This speculation, however, awaits further validation.
In conclusion, the present study unveiled a novel role for BDNF in central control of arterial pressure in the form of negative-feedback alleviation of Ang II-induced sustained oxidative stress in RVLM and long-term pressor response. It has been shown that BDNF deficiency plays a role in the etiology of cardiovascular diseases. 46 Our observations in SHRs thus suggest the possibility that disruption of BDNF/ TrkB signaling in RVLM may be an important cellular event in disease-dependent increases in oxidative stress. At the same time, our results raise the prospect that strategies focusing on augmentation of BDNF/TrkB cassette may prove clinically beneficial against oxidative stress-associated cardiovascular disorders. 
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Novelty and Significance
What Is Known?
• The rostral ventrolateral medulla (RVLM) is intimately related to the maintenance of arterial pressure. In RVLM, oxidative stress elicited by superoxide anion (O 2 . ) plays a pivotal role in neural regulation of hypertension by increasing sympathetic outflow to the peripheral blood vessels. • Oxidative stress in RVLM is attributable to an increase in NADPH oxidase activity, reduction in mitochondrial electron coupling capacity, and downregulation of the mitochondrial uncoupling protein (UCP). • One of the nontrophic actions of brain-derived neurotrophic factor (BDNF) exists in the form of antioxidant.
What New Information Does This Article Contribute?
• Activation of NADPH oxidase-derived O 2 . by angiotensin II (Ang II) transcriptionally upregulates BDNF in RVLM via phosphorylation of the redox-sensitive cAMP response element binding protein (CREB). • In RVLM, BDNF elicited by intracisternal infusion of Ang II attenuates the phosphorylation of NADPH oxidase, preserves mitochondrial electron coupling capacity, and upregulates UCP. • BDNF confers protection against Ang II-induced long-term pressor response and promotes antihypertension in spontaneously hypertensive rats (SHRs).
Given the pivotal role of oxidative stress in RVLM in the pathophysiology of hypertension, a better understanding of mechanisms for the maintenance of O 2 . homeostasis is of clinical significance. We report for the first time an active engagement of BDNF in oxidative stress-associated neurogenic hypertension via negative-feedback regulation of tissue O 2 . levels in RVLM. In normotensive rats, we found that acute and chronic Ang II treatment induced a NADPH oxidase-sensitive upregulation of BDNF in RVLM is mediated by the transcription factor CREB. Gene knockdown of BDNF further augmented the Ang II-induced O 2 . level in RVLM, indicating a feedback mechanism. We also found that that the upregulated BDNF could alleviate Ang II-induced oxidative stress in RVLM by at least 3 mechanisms: (1) suppression of Ang II-induced phosphorylation of p47 phox subunit of NADPH oxidase; (2) preservation of the mitochondrial electron coupling capacity in RVLM; and (3) upregulation of UCP. Finally, we established that BDNF in RVLM protects against Ang II-induced long-term pressor response and exerts an antihypertensive effects in SHRs. Our results suggest that strategies to augment BDNF may prove clinically beneficial against oxidative stress-associated cardiovascular disorders, including hypertension.
